Speaker Profile
Other, Head of Global Business Development, Axcelead Group
Biography
AI RD for drug discovery service. Axcelead is a CROCDMO spin-off startup from Takeda based in Japan with presence globally. The AI RD team is developing foundation models for drug discoveries utilizing both open source and proprietary models for insilico with validation for lab in the loop automation in Japan. Previous founder of Stanford spinoff for AI and genomics company focused on common complex diseases with focus on cardiac and CNS diseases. Degrees from Stanford and University of Chicago.
Talk
Comparative Foundation Model Approaches for Modeling ADMET Properties
In drug discovery, AI is also making an impact in protein structure predictions but there are still challenges for adoption in ADMET properties predictions. We explore a comparison between two of the most recent leading deep learning models, graph neural network (GNNs) and transformer based models to test their accuracy with our proprietary large-scale data.
AI and Data Sciences Showcase:
Axcelead Group
Axcelead is a leading Japanese biotech company spun out from Takeda with global partners. Our team includes hundreds expert chemist and AI to help our partners with insilico to wetlab validation in end to end services integrating the latest modelling techniques in AI.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
